XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.21
-1.12 (-2.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close47.33
Open47.34
Bid0.00 x 3200
Ask0.00 x 900
Day's Range45.41 - 47.34
52 Week Range37.01 - 59.59
Volume207,477
Avg. Volume307,323
Market Cap2.441B
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Acceleron Reports Second Quarter 2019 Operating and Financial Results

    - BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Age

  • Business Wire

    Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • Business Wire

    Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the urgency for new therapeutic options for patients with PAH,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron.

  • Business Wire

    Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Directors and will continue to serve the organization in an advisory capacity as Director Emeritus. “Tom co-founded Acceleron in 2003 and has been on the Board from day one,” said Francois Nader, MD, Chairman of Acceleron Pharma. “During this period, Tom’s unparalleled scientific instincts and acumen were instrumental in turning a belief in the promise of a fundamental biological pathway into a company on the verge of delivering its first product to patients.

  • Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
    Business Wire

    Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.

  • Business Wire

    Acceleron to Present at the UBS Global Healthcare Conference

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY. A live audio webcast will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

  • Business Wire

    Acceleron Reports First Quarter 2019 Operating and Financial Results

    – Luspatercept Biologics License Application and Marketing Authorization Application submitted in April 2019 –

  • Business Wire

    Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • Business Wire

    Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation.

  • Business Wire

    Acceleron Announces Departure of Chief Medical Officer

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K. Zeldin, M.D., Chief Medical Officer, is no longer employed by the company, as of today. The company has begun an executive search for his replacement.

  • Business Wire

    Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within The Ultimate Software Group, New Mountain Finance, Denny's, World Fuel Services, Agree Realty, and Acceleron Pharma — New Research Emphasizes Economic Growth

    NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire

    Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT). “This formal designation aligns with our mission to develop therapies for patients with rare diseases of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. “In clinical trials to date, treatment with ACE-083 has resulted in substantial increases in muscle volume in target muscles.

  • Business Wire

    Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    - MEDALIST and BELIEVE Phase 3 trial presentations at the 60th American Society of Hematology Annual Meeting both selected for “Best of ASH” -

  • Business Wire

    Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • Business Wire

    Acceleron to Present at Two Upcoming Healthcare Investor Conferences

    Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences.

  • GlobeNewswire

    Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire

    Acceleron Announces Pricing of Public Offering of Common Stock

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public offering of 5,348,838 shares of common stock at a price to the public of $43.00 per share for gross proceeds of $230.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 802,325 shares of common stock. Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-runners for the offering.

  • Business Wire

    Acceleron Announces Proposed Public Offering of Common Stock

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. As part of this offering, Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-running managers for the offering.

  • Business Wire

    Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of luspatercept in patients with red blood cell (RBC) transfusion-dependent and non-transfusion-dependent beta-thalassemia. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene. In this open-label, Phase 2 study (a three-month initial stage followed by a five-year extension stage), patients were treated with luspatercept subcutaneously once every three weeks.

  • Business Wire

    Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an overview of the company along with its upcoming corporate priorities at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San Francisco, California.

  • Business Wire

    Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology

    Acceleron Pharma Inc. (XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively, were selected for “Best of ASH” by the American Society of Hematology at its 60th Annual Meeting & Exposition in San Diego. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene. “Having both the MEDALIST and BELIEVE trials included in the Best of ASH session at the close of the annual meeting is extraordinarily gratifying,” said Habib Dable, President and Chief Executive Officer of Acceleron.

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire

    Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

    Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo